<p dir="ltr">Adrenomyeloneuropathy (AMN) is a rare adult-onset form of X-linked adrenoleukodystrophy caused by ABCD1 gene mutations. It leads to progressive weakness, spasticity in the legs, and adrenal dysfunction due to the buildup of very long-chain fatty acids. Treatment is mainly supportive, with ongoing research into disease-modifying options.</p>
<h2 dir="ltr"><strong>Epidemiology Segmentation</strong></h2>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Diagnosed Prevalent cases</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Total Treated cases</p>
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/adrenomyeloneuropathy-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Adrenomyeloneuropathy Epidemiology</strong></span></a></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, diagnosed prevalent cases of Adrenomyeloneuropathy in the 7MM were around 3.5K and are expected to rise by 2034.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">In 2024, the U.S. had approximately 1K diagnosed cases of Adrenomyeloneuropathy.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Germany recorded the highest number of diagnosed prevalent cases among the EU4 and the UK, accounting for over 27% of cases.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Japan had around 433 treated cases of Adrenomyeloneuropathy in 2024.</p>
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market"><span style="text-decoration: underline;"><strong>Adrenomyeloneuropathy Market</strong></span></a></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The Adrenomyeloneuropathy market size in the 7MM was USD 9.26 million in 2024.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The U.S. accounted for the largest share, around 45% of the total market.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Market growth is expected to be driven by rising prevalence, low competition, and increased public awareness efforts.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Adrenomyeloneuropathy Market Drivers</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Increasing use of next-generation sequencing and newborn screening is enabling earlier and more accurate diagnosis of AMN, driving demand for targeted therapies.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Ongoing research and clinical trials exploring gene therapy, stem cell treatments, and metabolic interventions are fueling optimism and investment in the AMN treatment landscape.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Adrenomyeloneuropathy Market Barriers</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">The absence of curative or disease-modifying therapies limits treatment options, discouraging large-scale investment from some pharmaceutical players.</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Being a rare condition, AMN often faces delayed diagnosis or misidentification, which hampers timely intervention and market expansion.</p>
</li>
</ul>
<h3 dir="ltr"><strong>Adrenomyeloneuropathy Key Therapies</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Leriglitazone</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">SBT101</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">VK0214</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Adrenomyeloneuropathy (AMN)</p>
</li>
</ul>
<p dir="ltr">And others.&nbsp;</p>
<h3 dir="ltr"><strong>Adrenomyeloneuropathy Key Players</strong></h3>
<ul>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Minoryx Therapeutics</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Spur Therapeutics</p>
</li>
<li dir="ltr" aria-level="1">
<p dir="ltr" role="presentation">Viking Therapeutics</p>
</li>
</ul>
<p dir="ltr">And others.</p>

Adrenomyeloneuropathy Market

Adrenomyeloneuropathy Market Infographic

Adrenomyeloneuropathy Market Thumbnail

Adrenomyeloneuropathy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape